Pfizer Reports Updated Data from Phase III Study on Ibrance


Category: topSource: redinewsDec 7th, 2017

Bristol-Myers Reports Data from Opdivo Combination Studies

Bristol-Myers (BMY) presented multiple data from Opdivo combination studies. Bristol-Myers Squibb Company BMY announced updated results from the multi-arm phase Ib study, CheckMate -012, evaluating the safety and tolerability (primary endpoints.....»»

Category: topSource: zacksDec 6th, 2016

Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress

− Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Myeloma Remains on Track; Top-Line Data Expected end of April 2018 –.....»»

Category: earningsSource: benzingaMar 15th, 2018

Anthera Pharmaceuticals (ANTH) Reports Top Line Data From The RESULT Phase 3 Clinical Study Of Sollpura - Slideshow

Anthera Pharmaceuticals (ANTH) Reports Top Line Data From The RESULT Phase 3 Clinical Study Of Sollpura - Slideshow.....»»

Category: topSource: seekingalphaMar 13th, 2018

Epizyme Reports Fourth Quarter and Full Year 2017 Operating Results and 2018 Milestones

First Tazemetostat NDA Submission for Epithelioid Sarcoma Targeted for Fourth Quarter of 2018; Second Tazemetostat NDA Submission for Follicular Lymphoma Targeted for 2019 Multiple Phase 2 Study Data Readouts Planned in 2018 Confer.....»»

Category: earningsSource: benzingaMar 13th, 2018

Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress

Initial Clinical Data of FATE-NK100 in Relapsed / Refractory AML Show Rapid Reduction of Leukemic Blasts in the Bone Marrow All Subjects in PROTECT Phase 1 Study of ProTmune Ac.....»»

Category: earningsSource: benzingaMar 5th, 2018

Merck Reports Positive Phase III Liver Cancer Data on Keytruda

Merck (MRK), announces first time results from the phase II study evaluating the use Keytruda in patients with advanced hepatocellular carcinoma (HCC), previously treated with sorafenib. Merck & Co., Inc. MRK announced data f.....»»

Category: personnelSource: nytJan 22nd, 2018

Bristol-Myers (BMY) Reports Data from CheckMate-142 Study

Bristol-Myers (BMY) announces new data from a cohort of the phase II CheckMate -142 study evaluating Opdivo (nivolumab) and Yervoy (ipilimumab). Bristol-Myers Squibb Company BMY announced new d.....»»

Category: dealsSource: nytJan 22nd, 2018

Momenta Reports Positive Top-Line Data on Antibody M281

Momenta reported positive top-line results from a phase I study on M281 wherein the candidate did not show any adverse event.....»»

Category: smallbizSource: nytJan 8th, 2018

Juno Reports Additional Data on CAR-T Therapy, Shares Drop

Juno (JUNO) releases additional results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate, JCAR017. Juno Therapeutics, Inc. JUNO along with partner Celgene Corporation CE.....»»

Category: worldSource: nytDec 12th, 2017

Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug

Bristol-Myers Squibb Company (BMY) announced positive data from an ongoing phase II study on leukemia drug Sprycel in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years. .....»»

Category: worldSource: nytDec 12th, 2017

Gilead (GILD) Posts Updated Data on CAR-T Therapy Yescarta

Gilead (GILD) announced follow-up data from a phase II study, on its CAR-T therapy, Yescarta for treatment of refractory large B-cell lymphoma. Gilead Sciences Inc. GILD announced long-term follow-up.....»»

Category: dealsSource: nytDec 11th, 2017

Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi

Incyte (INCY) announced new 208-week (4-year) follow-up data from the phase III RESPONSE study of Jakafi. Incyte Corporation INCY announced a new 208-week (4-year) follow-up data from the phase III RESPONSE study of Jakafi. The .....»»

Category: worldSource: nytDec 11th, 2017

Roche Reports Tecentriq/Avastin Lung Cancer Study Data

Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer. Roche’s RHHBY member Genentech, annou.....»»

Category: personnelSource: nytDec 7th, 2017

Jounce Therapeutics Reports Third Quarter 2017 Financial Results

- Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC study in 1H 2018 - - Strengthen leadership team and board with key new appointmen.....»»

Category: earningsSource: benzingaNov 13th, 2017

46 Stocks Moving In Wednesday"s Mid-Day Session

Gainers OncoSec Medical Inc (NASDAQ: ONCS) shares climbed 49.6 percent to $1.87 after the company disclosed positive updated long-term follow-up data from its Phase 2 OMS I-102 combination study of ImmunoPulse® IL-12 and pembrolizumab. read more.....»»

Category: blogSource: benzingaNov 8th, 2017

Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda

Incyte Corporation (INCY) announced new and updated data from the ongoing phase I/II ECHO-202 trial on pipeline candidate epacadostat with Keytruda. Incyte Corporation INCY announced that the European S.....»»

Category: smallbizSource: nytSep 1st, 2017

Jounce Therapeutics Reports Second Quarter 2017 Financial Results

- Presented Phase 1 data from ICONIC study of JTX-2011 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting - - Initiated Phase 2 portion of ICONIC study evaluating JTX-2011 in advanced solid tumors in.....»»

Category: earningsSource: benzingaAug 9th, 2017

Ironwood (IRWD) Reports Positive Data on Reflux Candidate

Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease. Ironwood Pharmaceuticals, Inc. IRWD announced positive top-l.....»»

Category: topSource: zacksJul 21st, 2017

Paratek Antibiotic Candidate"s Phase III Data Favorable

Paratek Pharmaceuticals, Inc. (PRTK) announced positive results from a phase III study (OASIS-2) comparing its antibiotic candidate omadacycline to Pfizer Inc.'s (PFE) Zyvox for the treatment of acute bacterial.....»»

Category: topSource: zacksJul 18th, 2017